Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-101 in healthy volunteers (safety lead-in for pre-eclampsia)
NCT07327255Phase 1Not yet recruiting
- Sponsor
- Evergreen Therapeutics, Inc.
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of EG-101 in preeclampsia, sponsored by Evergreen Therapeutics, Inc. Primary endpoints: Time to Maximum Plasma Concentration at 32 hours, Maximum Plasma Concentration at 32 hours and 5 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
EG-101
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT07327255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327255.